Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?
Cancers · 24.07.2025 · 17 (15) · 2453
DOI: 10.3390/cancers17152453 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.07.2025. Verfasst von Kamila Krupa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Students' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), ranks among the most lethal malignancies, with a 5-year survival rate of under 10%. The most prevalent KRAS mutations occur in three hotspot residues: glycine-12 (G12), glycine-13 (G13), and glutamine-61 (Q61), leading to the constant activation of the Ras pathway, making them the primary focus in oncologic drug development. Selective KRAS G12C inhibitors (e.g., sotorasib, adagrasib) have demonstrated moderate efficacy in clinical trials; however, this mutation is infrequent in PDAC. Emerging therapies targeting KRAS G12D and G12V mutations, such as MRTX1133, PROTACs, and active-state inhibitors, show promise in preclinical studies. Pan-RAS inhibitors like ADT-007, RMC-9805, and RMC-6236 compounds provide broader coverage of mutations. Their efficacy and safety are currently being investigated in several clinical trials. A major challenge is the development of resistance mechanisms, including secondary mutations and pathway reactivation. Combination therapies targeting the RAS/MAPK axis, SHP2, mTOR, or SOS1 are under clinical investigation. Immunotherapy alone has demonstrated limited effectiveness, attributed to an immunosuppressive tumor microenvironment, although synergistic effects are noted when paired with KRAS-targeted agents. Furthermore, KRAS mutations reprogram cancer metabolism, enhancing glycolysis, macropinocytosis, and autophagy, which are being explored therapeutically. RNA interference technologies have also shown potential in silencing mutant KRAS and reducing tumorigenicity. Future strategies should emphasize the combination of targeted therapies with metabolic or immunomodulatory agents to overcome resistance and enhance survival in KRAS-mutated PDAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Students' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
- Department of Oncological Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
- Department of Oncology, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland.
- Department of Health Economics and Medical Law, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Department of Economic and System Analyses, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.
ORCID-Profile: Kamila Krupa, Marta Fudalej, Michał P Budzik, Aleksandra Czerw, Andrzej Deptała
Zitieren
APA
Krupa, K., Fudalej, M., Włoszek, E., Miski, H., Badowska-Kozakiewicz, A. M., Mękal, D., Budzik, M. P., Czerw, A., & Deptała, A. (2025). Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?. Cancers, 17(15), 2453. https://doi.org/10.3390/cancers17152453
Vancouver
Krupa K, Fudalej M, Włoszek E, Miski H, Badowska-Kozakiewicz AM, Mękal D, et al. Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?. Cancers. 2025;17(15):2453. doi:10.3390/cancers17152453
BibTeX
@article{Krupa2025,
author = {Krupa, Kamila and Fudalej, Marta and Włoszek, Emilia and Miski, Hanna and Badowska-Kozakiewicz, Anna M and Mękal, Dominika and Budzik, Michał P and Czerw, Aleksandra and Deptała, Andrzej},
title = {Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?},
journal = {Cancers},
year = {2025},
volume = {17},
number = {15},
pages = {2453},
doi = {10.3390/cancers17152453}
}
EUVIMED